Arena Pharmaceuticals (ARNA -0.1%) enters into a co-development and license agreement with...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

Arena Pharmaceuticals (ARNA -0.1%) enters into a co-development and license agreement with Ildong Pharmaceutical for Temanogrel, ARNA's treatment for for myocardial infarction, acute coronary syndrome, stroke, peripheral artery disease, and other cardiovascular diseases, subject to the drug's further development and regulatory approval. The agreement grants Ildong exclusive rights to commercialize and market the drug.